Status:
COMPLETED
Selara Drug Use Investigation (Regulatory Post Marketing Commitment Plan)
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Hypertension
Eligibility:
All Genders
Brief Summary
To collect the efficacy and safety information of Eplerenone on patients with hypertension related to their appropriate use in daily practice.
Eligibility Criteria
Inclusion
- Male or Female patients who are prescribed Selara tablet for Hypertension.
Exclusion
- Subjects who have been prescribed Selara tablet.
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2012
Estimated Enrollment :
3338 Patients enrolled
Trial Details
Trial ID
NCT00749775
Start Date
June 1 2008
End Date
December 1 2012
Last Update
December 22 2020
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.